ExoASO-STAT6 is an exosome-based therapeutic drug that converts tumor-associated macrophages (TAMs) from an immunosuppressive M2 phenotype to a proinflammatory M1 phenotype by delivering antisense oligonucleotides (ASOs) targeting STAT6 to enhance antitumor immune responses.A recent study found that this medication dramatically slowed tumor growth and even achieved complete remission, while also demonstrating notable inhibitory effects on liver metastases. Here, STAT6 is linked to neoplasm.